Drug intelligence / Profile preview

11C-T-1650

Development stage: Phase 2
Lead developer: Tetra Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

11C-T-1650 is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It functions as a PDE4D (phosphodiesterase 4D) inhibitor and is used for PET imaging to measure PDE4D in the brain and body. The drug was initially developed by Tetra Therapeutics Inc. and has been studied in clinical trials to evaluate its effectiveness as a novel PET radioligand for phosphodiesterase-4D.

Targets

PDE4D (Phosphodiesterase 4D)

Beyond the preview

Go deeper on 11C-T-1650.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11C-T-1650.